Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes : Hypothetical Case Studies

Show simple item record

dc.contributor.author Harris, Stewart B.
dc.contributor.author Parente, Erika B.
dc.contributor.author Karalliedde, Janaka
dc.date.accessioned 2022-05-13T10:52:06Z
dc.date.available 2022-05-13T10:52:06Z
dc.date.issued 2022-05
dc.identifier.citation Harris , S B , Parente , E B & Karalliedde , J 2022 , ' Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes : Hypothetical Case Studies ' , Diabetes therapy , vol. 13 , no. 5 , pp. 913-930 . https://doi.org/10.1007/s13300-022-01247-7
dc.identifier.other PURE: 208035305
dc.identifier.other PURE UUID: 2eab767e-991a-4114-b46c-6369b4f04da6
dc.identifier.other WOS: 000776817800001
dc.identifier.other ORCID: /0000-0002-8101-912X/work/113023249
dc.identifier.uri http://hdl.handle.net/10138/343688
dc.description.abstract Type 2 diabetes (T2D) is a progressive disease, with many individuals eventually requiring basal insulin therapy to maintain glycaemic control. However, there exists considerable therapeutic inertia to the prompt initiation and optimal titration of basal insulin therapy due to barriers that include fear of injections, hypoglycaemia, weight gain, and burdensome regimens. Hypoglycaemia is thought to be a major barrier to optimal glycaemic control and is associated with significant morbidity and mortality. Newer second-generation basal insulin analogues provide comparable glycaemic control with lower risk of hypoglycaemia compared with first-generation basal insulin analogues. The present review article discusses clinical evidence for one such second-generation basal insulin analogue, insulin glargine 300 U/mL (Gla-300), in the context of hypothetical case studies that are representative of individuals who may attend routine clinical practice. These case studies discuss individualised treatment needs for people with T2D who are insulin-naive or pre-treated. Clinical characteristics such as older age, frequent nocturnal hypoglycaemia, and renal impairment, which are known risk factors for hypoglycaemia, are also considered. en
dc.format.extent 18
dc.language.iso eng
dc.relation.ispartof Diabetes therapy
dc.rights cc_by_nc
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject Basal insulin analogues
dc.subject Glycaemic control
dc.subject Hypoglycaemia
dc.subject Insulin glargine 300 U
dc.subject mL
dc.subject Type 2 diabetes
dc.subject GLYCEMIC CONTROL
dc.subject BASAL INSULIN
dc.subject SEVERE HYPOGLYCEMIA
dc.subject ELDERLY-PATIENTS
dc.subject GLUCOSE CONTROL
dc.subject 100 UNITS/ML
dc.subject PEOPLE
dc.subject TRIAL
dc.subject OUTCOMES
dc.subject PATHOPHYSIOLOGY
dc.subject 3121 General medicine, internal medicine and other clinical medicine
dc.title Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes : Hypothetical Case Studies en
dc.type Review Article
dc.contributor.organization CAMM - Research Program for Clinical and Molecular Metabolism
dc.contributor.organization University of Helsinki
dc.contributor.organization Nefrologian yksikkö
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1007/s13300-022-01247-7
dc.relation.issn 1869-6953
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
Harris2022_Arti ... UseOfInsulinGlargine30.pdf 851.9Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record